CytoMed Therapeutics Limited

NasdaqCM GDTC

CytoMed Therapeutics Limited Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -2.14 M

CytoMed Therapeutics Limited Net Cash Used For Investing Activities is USD -2.14 M for the year ending December 31, 2023, a -507.68% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.
  • CytoMed Therapeutics Limited Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -351.60 K, a 42.27% change year over year.
  • CytoMed Therapeutics Limited Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -609.05 K, a -57.14% change year over year.
  • CytoMed Therapeutics Limited Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -387.57 K, a 39.72% change year over year.
  • CytoMed Therapeutics Limited Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -643.00 K.
Key data
Date Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure
Market news
Loading...
SV Wall Street
NasdaqCM: GDTC

CytoMed Therapeutics Limited

CEO Mr. Chee Kong Choo
IPO Date April 14, 2023
Location Singapore
Headquarters 1 Commonwealth Lane, No. 08-22
Employees 28
Sector Healthcare
Industries
Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

Similar companies

SILO

Silo Pharma, Inc.

USD 1.63

-1.81%

IKT

Inhibikase Therapeutics, Inc.

USD 2.35

-3.29%

MNPR

Monopar Therapeutics Inc.

USD 48.46

2.87%

OKYO

OKYO Pharma Limited

USD 1.06

-3.64%

LVTX

LAVA Therapeutics N.V.

USD 0.98

-1.01%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.57

1.95%

CADL

Candel Therapeutics, Inc.

USD 8.66

11.03%

SNTI

Senti Biosciences, Inc.

USD 4.15

-4.16%

StockViz Staff

February 8, 2025

Any question? Send us an email